Click Therapeutics™ Reports Preliminary Results of a 416-Participant Clinical Study Demonstrating Exceptional Engagement and Efficacy of Clickotine®, a Patent-Pending Digital Therapeutics™ Program for Smoking Cessation (press release):
“Click Therapeutics, Inc. (“Click”), a company developing a suite of personalized data-driven digital therapeutics for chronic health conditions, announces today preliminary results of its fully remote clinical trial of Clickotine, a digital program designed for smoking cessation.
The study was conducted to investigate the feasibility of a fully digital clinical trial, to validate the engagement of the CLICK Neurobehavioral Intervention (CNI) Platform, and to explore the efficacy of Clickotine for smoking cessation…In a digital, 8‑week, IRB-approved open-label clinical trial, Clickotine was provided to 416 participants who enrolled in the trial over the 9‑week period of recruitment…According to Nicholas Schork, Ph.D., the Principal Investigator of the Clickotine trial and also a Professor at the J. Craig Venter Institute as well as the Translational Genomics Research Institute: “This study demonstrates the potential of conducting a trial of a therapeutic intervention digitally. The user engagement, data integrity, and efficiency provided by the Click platform were exceptional”…Click is planning a large-scale randomized controlled clinical trial to confirm these results.
To learn more:
- Meet Dr. Brian Iacoviello, Director of Scientific Affairs at Click Therapeutics, at the upcoming 2016 SharpBrains Virtual Summit (December 6–8th)